The present invention relates to a pharmaceutical composition comprising an artemisinin compound, and 5-aminolevulinic acid or methyl-5-aminolevulinic acid and at least one chemotherapeutic agent, preferably at least one anti-glioblastoma drug. This pharmaceutical composition is used for the prophylaxis and/or treatment of hematopoietic cancers, brain cancer, pancreatic cancer, liver cancer, breast cancer, and lung cancer such as non-small cell lung cancer. Preferably, the present application provides a pharmaceutical composition comprising artemisinin (1a) or di-hydroarteminisin (1b) or artesunate (1e) and 5-aminolevulinic acid (2) or methyl-5- aminolevulinic acid (2b) and at least one chemotherapeutic agent, preferably at least one anti-glioblastoma drug for use in prophylaxis and/or treatment of brain cancer, in particular glioblastoma.

The present invention relates to a pharmaceutical composition comprising an artemisinin compound, and 5-aminolevulinic acid or methyl-5-aminolevulinic acid and at least one chemotherapeutic agent, preferably at least one anti-glioblastoma drug. This pharmaceutical composition is used for the prophylaxis and/or treatment of hematopoietic cancers, brain cancer, pancreatic cancer, liver cancer, breast cancer, and lung cancer such as non-small cell lung cancer. Preferably, the present application provides a pharmaceutical composition comprising artemisinin (1a) or di-hydroarteminisin (1b) or artesunate (1e) and 5-aminolevulinic acid (2) or methyl-5- aminolevulinic acid (2b) and at least one chemotherapeutic agent, preferably at least one anti-glioblastoma drug for use in prophylaxis and/or treatment of brain cancer, in particular glioblastoma.

The present invention relates to a pharmaceutical composition comprising an artemisinin compound, and 5-aminolevulinic acid or methyl-5-aminolevulinic acid and at least one chemotherapeutic agent, preferably at least one anti-glioblastoma drug. This pharmaceutical composition is used for the prophylaxis and/or treatment of hematopoietic cancers, brain cancer, pancreatic cancer, liver cancer, breast cancer, and lung cancer such as non-small cell lung cancer. Preferably, the present application provides a pharmaceutical composition comprising artemisinin (1a) or di-hydroarteminisin (1b) or artesunate (1e) and 5-aminolevulinic acid (2) or methyl-5- aminolevulinic acid (2b) and at least one chemotherapeutic agent, preferably at least one anti-glioblastoma drug for use in prophylaxis and/or treatment of brain cancer, in particular glioblastoma.

The present invention relates to a pharmaceutical composition comprising at least one Vitamin of the group D, lycopene, at least one flavonoid, at least one terpene and at least one calcium salt of a (C.sub.1-C.sub.3) carboxylic acid for use in the treatment of one or more menstrual disorders selected from the group consisting of Dysmenorrhea and Premenstrual syndrome (PMS).

The present invention relates to a pharmaceutical composition comprising at least one Vitamin of the group D, lycopene, at least one flavonoid, at least one terpene and at least one calcium salt of a (C.sub.1-C.sub.3) carboxylic acid for use in the treatment of one or more menstrual disorders selected from the group consisting of Dysmenorrhea and Premenstrual syndrome (PMS).

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions by enhancing systemic level of nitric oxide.

A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions by enhancing systemic level of nitric oxide.